SPYBIOTECH LIMITED

Active United Kingdom

Research and experimental development on biotechnology

21 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
S

SPYBIOTECH LIMITED

Research and experimental development on biotechnology

Founded 2 Mar 2017 Active United Kingdom 21 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 12 Nov 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 30 Apr 2026 Next due 15 Mar 2027 9 months remaining
Net assets £5M £6M 2024 year on year
Total assets £8M £7M 2024 year on year
Total Liabilities £3M £510K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Telephone

0800 000 0000

Website

www.example.com

Full company profile for SPYBIOTECH LIMITED (10649320), an active life sciences and medical technology company based in United Kingdom. Incorporated 2 Mar 2017. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type group
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2022–2024)

Cash in Bank

£5.82M

Decreased by £6.35M (-52%)

Net Assets

£4.52M

Decreased by £6.27M (-58%)

Total Liabilities

£3.16M

Decreased by £509.89k (-14%)

Turnover

N/A

Employees

21

Increased by 4 (+24%)

Debt Ratio

41%

Increased by 16 (+64%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (5)

Investor NameInvestor SinceParticipating Rounds
Investor 2Mar 2017Series A, Seed
Investor 5Mar 2017Series A, Seed
Investor 3Feb 2021Series A

Share Capital

Share Capital

Share allotments and capital structure

12 Allotments 10,085,830 Shares £24.84m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
1 Sept 2025104,315£70k£0.67
19 Nov 20243,784£113.52£0.03
26 Jun 202419,560£19.56£0.001
25 Jan 202478,245£78.245£0.001
25 Jan 20246,150£184.5£0.03

Officers

Officers

2 active 1 resigned
Status
Chaffee, Stuart, DrDirectorAmericanUnited States5231 Jul 2025Active
Crawford-brunt, AndreDirectorSouth AfricanEngland555 Feb 2021Active

Shareholders

Shareholders (21)

Oxford Science Enterprises Plc
22.2%
4,000,000
Braavos Capital Gp Limited
18.5%
3,333,333

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased
Active
Notified 2 Mar 2018
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Group Structure

Group Structure

SPYBIOTECH LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

1 leasehold 1 total
AddressTenurePrice PaidDate Added
Unit C2 - 7600, The Quorum, Alec Issigonis Way, Oxford Business Park North, Oxford (OX4 2JZ) OXFORD
Leasehold-8 Dec 2021
Unit C2 - 7600, The Quorum, Alec Issigonis Way, Oxford Business Park North, Oxford (OX4 2JZ)
Leasehold
Added 8 Dec 2021
District OXFORD

Documents

Company Filings

DateCategoryDescriptionDocument
30 Apr 2026Confirmation StatementConfirmation statement made on 1 Mar 2026 with updates
29 Apr 2026OfficersChange to director Mr Stuart Chaffee on 29 Apr 2026
6 Dec 2025OfficersTermination of Mark Leuchtenberger as director on 26 Nov 2025
12 Nov 2025AccountsAnnual accounts made up to 31 Dec 2024
18 Sept 2025CapitalAllotment of shares (GBP 6,625.482) on 10 Sept 2025
30 Apr 2026 Confirmation Statement

Confirmation statement made on 1 Mar 2026 with updates

29 Apr 2026 Officers

Change to director Mr Stuart Chaffee on 29 Apr 2026

6 Dec 2025 Officers

Termination of Mark Leuchtenberger as director on 26 Nov 2025

12 Nov 2025 Accounts

Annual accounts made up to 31 Dec 2024

18 Sept 2025 Capital

Allotment of shares (GBP 6,625.482) on 10 Sept 2025

Recent Activity

Latest Activity

Confirmation statement made on 1 Mar 2026 with updates

1 months ago on 30 Apr 2026

Change to director Mr Stuart Chaffee on 29 Apr 2026

1 months ago on 29 Apr 2026

Termination of Mark Leuchtenberger as director on 26 Nov 2025

6 months ago on 6 Dec 2025

Annual accounts made up to 31 Dec 2024

6 months ago on 12 Nov 2025

Allotment of shares (GBP 6,625.482) on 10 Sept 2025

8 months ago on 18 Sept 2025